2seventy Bio, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Glazer Capital, LLC and Paul J. Glazer have reported a complete divestment of their beneficial ownership in 2seventy bio, Inc., holding 0% of common stock.
Beryl Capital Management and its affiliates have reported a complete divestiture of their beneficial ownership in 2seventy bio, Inc., holding 0% of common stock.
Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC reported a negligible 0.0% beneficial ownership in 2SEVENTY BIO, INC. common stock.